Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 2/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31341960 | 0.85 | CSNK2A1 (0.38) | CSNK2A1TNFRIPK1AHREGFR | |
| SCHEMBL31527469 | 0.85 | CSNK2A1 (0.38) | CSNK2A1TNFRIPK1AHREGFR | |
| SCHEMBL16004965 | 0.81 | AHR (0.35) | CSNK2A1TNFRIPK1AHRRHEB | |
| SCHEMBL26129610 | 0.81 | CSNK2A1 (0.44) | CSNK2A1TNFRIPK1AHREGFR | |
| SCHEMBL30144058 | 0.81 | AHR (0.35) | CSNK2A1TNFRIPK1AHRRHEB | |
| SCHEMBL24787431 | 0.78 | CSNK2A1 (0.42) | CSNK2A1AHREGFRRHEBCCR8 | |
| SCHEMBL24787449 | 0.78 | TNF (0.47) | CSNK2A1TNFRIPK1AHREGFR | |
| SCHEMBL26145372 | 0.78 | CSNK2A1 (0.42) | CSNK2A1AHREGFRRHEBCCR8 | |
| SCHEMBL24215565 | 0.77 | TNF (0.41) | CSNK2A1TNFRIPK1AHRRHEB | |
| SCHEMBL12748352 | 0.75 | TNF (0.38) | TNFRIPK1AHRRHEBCCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522603-B2 | Inhibitors of gas for treating autoinflammatory diseases and cancer metastasis | THE ROCKEFELLER UNIVERSITY (US) | 2026-01-13 | — | — | US | disclosed |
| EP-3937932-B1 | INHIBITORS OF CGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS | UNIV ROCKEFELLER (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
| US-11414422-B2 | Substituted pyrido[4,3-b]indoles and azepino[4,5-b]indoles as inhibitors of cGAS | THE ROCKEFELLER UNIVERSITY (US) | 2022-08-16 | — | — | US | disclosed |
| CN-114901279-A | Inhibitors of cGAS for the treatment of autoinflammatory diseases and cancer metastasis | 洛克菲勒大学 | 2022-08-12 | — | — | CN | disclosed |
| US-20220185812-A1 | INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS | THE ROCKEFELLER UNIVERSITY (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3749293-B1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4, 3-B]INDOLE INHIBITORS OF CGAS FOR TREATING AUTOINFLAMMATORY DISEASES | UNIV ROCKEFELLER (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3937932-A1 | INHIBITORS OF CGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS | Tomita, Daisuke (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210155625-A1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4, 3-b]INDOLE INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210155625-A1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4, 3-b]INDOLE INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2021-05-27 | — | — | US | disclosed |
| WO-2020186027-A1 | INHIBITORS OF CGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS | TOMITA DAISUKE (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020186027-A1 | INHIBITORS OF CGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS | TOMITA DAISUKE (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2019153002-A1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4, 3-B]INDOLE INHIBITORS OF CGAS FOR TREATING AUTOINFLAMMATORY DISEASES | LAMA LODOE (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414422-B2 | Substituted pyrido[4,3-b]indoles and azepino[4,5-b]indoles as inhibitors of cGAS | CGAS, STING1, IRF3 | CSNK2A1 968/4885TNF 2327/4885RIPK1 782/4885 |
| US-20220185812-A1 | INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS | CGAS, STING1, IRF3 | CSNK2A1 2393/4885TNF 628/4885RIPK1 212/4885 |
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | CSNK2A1 238/4885TNF 1330/4885RIPK1 652/4885 |
| US-20210155625-A1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4, 3-b]INDOLE INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES | STING1, IRF3, CGAS | CSNK2A1 1764/4885TNF 834/4885RIPK1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.